{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:38:03Z","timestamp":1790951883006,"version":"4.1.0"},"reference-count":32,"publisher":"The Endocrine Society","issue":"3","license":[{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,18]]},"abstract":"Abstract<\/jats:title>\n \n Context<\/jats:title>\n Romosozumab, a monoclonal sclerostin antibody, is a recently approved highly potent antiosteoporotic agent with osteoanabolic properties. Clinical use of romosozumab is hindered by the fear of adverse cardiovascular (CV) events raised following the pivotal ARCH trial.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n This work aimed to assess real-world CV safety of romosozumab vs alternative osteoanabolic therapies used for treatment of severe osteoporosis.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Data were obtained from TriNetX, a global federated health research network including real-time electronic medical records from 113 health care organizations with 136 460 930 patients across 16 countries at time of analysis. Inclusion criteria were age 40 years or older, a diagnosis of osteoporosis and prescription of romosozumab or a parathyroid hormone (PTH) analogue (teriparatide\/abaloparatide) during August 2019 through August 2022. Propensity-score-matched cohorts were created 1:1 using demographic variables, comorbidities, and medications. Kaplan-Meier analysis was used to estimate the probability of the outcomes. Outcome measures included incident 3-point major adverse CV event or death (3P-MACE) during 1-year of follow-up after the initial prescription.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 5626 and 15 986 patients met the criteria for romosozumab and PTH analogue cohorts, respectively, with 5610 patients per group following propensity score matching. 3P-MACE was significantly less frequent in the romosozumab vs PTH analogue cohort (158 vs 211 patients with an outcome; P = .003) with reductions in the individual components of the composite outcome: myocardial ischemic events (31 vs 58; P = .003); cerebrovascular events 56 vs 79; P = .037; deaths (83 vs 104; P = .099).<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n In a diverse, real-world setting, prescription of romosozumab for osteoporosis is associated with fewer adverse CV events when compared to PTH analogue therapy.<\/jats:p>\n <\/jats:sec>","DOI":"10.1210\/clinem\/dgae173","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T04:32:17Z","timestamp":1710390737000},"page":"e861-e867","source":"Crossref","is-referenced-by-count":50,"title":["Cardiovascular Safety of Romosozumab vs PTH Analogues for Osteoporosis Treatment: A Propensity-Score-Matched Cohort Study"],"prefix":"10.1210","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4939-5800","authenticated-orcid":false,"given":"Joshua","family":"Stokar","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Osteoporosis Center, Hadassah Medical Center, The Hebrew University of Jerusalem , 9124001 Jerusalem ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auryan","family":"Szalat","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Osteoporosis Center, Hadassah Medical Center, The Hebrew University of Jerusalem , 9124001 Jerusalem ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,3,14]]},"reference":[{"issue":"15","key":"2025021815502595800_dgae173-B1","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"issue":"16","key":"2025021815502595800_dgae173-B2","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"2025021815502595800_dgae173-B3","first-page":"1244","article-title":"A harmonized data quality assessment terminology and framework for the secondary use of electronic health record data","volume":"4","author":"Kahn","year":"2016","journal-title":"EGEMS (Wash DC)"},{"key":"2025021815502595800_dgae173-B4","doi-asserted-by":"crossref","first-page":"103847","DOI":"10.1016\/j.jbi.2021.103847","article-title":"Assessing real-world medication data completeness","volume":"119","author":"Evans","year":"2021","journal-title":"J Biomed Inform"},{"issue":"2","key":"2025021815502595800_dgae173-B5","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S2215-0366(20)30462-4","article-title":"Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA","volume":"8","author":"Taquet","year":"2021","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"2025021815502595800_dgae173-B6","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41591-023-02672-2","article-title":"Association of semaglutide with risk of suicidal ideation in a real-world cohort","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"issue":"7","key":"2025021815502595800_dgae173-B7","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1001\/jama.2022.0210","article-title":"Comparison of mRNA-1273 and BNT162b2 vaccines on breakthrough SARS-CoV-2 infections, hospitalizations, and death during the delta-predominant period","volume":"327","author":"Wang","year":"2022","journal-title":"JAMA"},{"issue":"8","key":"2025021815502595800_dgae173-B8","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jamapediatrics.2022.0945","article-title":"Incidence rates and clinical outcomes of SARS-CoV-2 infection with the omicron and delta variants in children younger than 5 years in the US","volume":"176","author":"Wang","year":"2022","journal-title":"JAMA Pediatr"},{"issue":"11","key":"2025021815502595800_dgae173-B9","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1210\/clinem\/dgaa450","article-title":"Cardiovascular safety of abaloparatide in postmenopausal women with osteoporosis: analysis from the ACTIVE phase 3 trial","volume":"105","author":"Cosman","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2025021815502595800_dgae173-B10","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s00198-022-06413-y","article-title":"Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: a US administrative claims database study","volume":"33","author":"Cosman","year":"2022","journal-title":"Osteoporos Int"},{"key":"2025021815502595800_dgae173-B11","doi-asserted-by":"crossref","first-page":"116647","DOI":"10.1016\/j.bone.2022.116647","article-title":"Cardiac adverse events in bisphosphonate and teriparatide users: an international pharmacovigilance study","volume":"168","author":"Rodr\u00edguez","year":"2023","journal-title":"Bone"},{"issue":"1","key":"2025021815502595800_dgae173-B12","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1186\/s12913-018-3727-0","article-title":"Positive predictive value of ICD-10 codes for acute myocardial infarction in Japan: a validation study at a single center","volume":"18","author":"Ando","year":"2018","journal-title":"BMC Health Serv Res"},{"key":"2025021815502595800_dgae173-B13","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/CLEP.S288518","article-title":"Validation of ICD-10-CM diagnosis codes for identification of patients with acute hemorrhagic stroke in a national health insurance claims database","volume":"13","author":"Hsieh","year":"2021","journal-title":"Clin Epidemiol"},{"issue":"12","key":"2025021815502595800_dgae173-B14","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1002\/pds.5675","article-title":"Validation of ICD-10 hospital discharge diagnosis codes to identify incident and recurrent ischemic stroke from a US integrated healthcare system","volume":"32","author":"Shirley","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"2025021815502595800_dgae173-B15","first-page":"e009078","article-title":"Validity of international classification of diseases (ICD)-10 diagnosis codes for identification of acute heart failure hospitalization and heart failure with reduced versus preserved ejection fraction in a national medicare sample","volume":"16","author":"Bates","year":"2023","journal-title":"Circulation"},{"key":"2025021815502595800_dgae173-B16","author":"Administration USFaD"},{"key":"2025021815502595800_dgae173-B17","author":"Health EMA-SM"},{"key":"2025021815502595800_dgae173-B18"},{"issue":"6","key":"2025021815502595800_dgae173-B19","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s00198-020-05379-z","article-title":"Explanations for the difference in rates of cardiovascular events in a trial of alendronate and romosozumab","volume":"31","author":"Cummings","year":"2020","journal-title":"Osteoporos Int"},{"issue":"12","key":"2025021815502595800_dgae173-B20","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1080\/14740338.2022.2160445","article-title":"What is the risk of cardiovascular events in osteoporotic patients treated with romosozumab?","volume":"21","author":"Reid","year":"2022","journal-title":"Expert Opin Drug Saf"},{"issue":"9","key":"2025021815502595800_dgae173-B21","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1210\/jc.2017-02163","article-title":"A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis","volume":"103","author":"Lewiecki","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"10102","key":"2025021815502595800_dgae173-B22","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"key":"2025021815502595800_dgae173-B23","doi-asserted-by":"crossref","first-page":"116610","DOI":"10.1016\/j.bone.2022.116610","article-title":"Evidence for the cardiovascular effects of osteoporosis treatments in randomized trials of post-menopausal women: a systematic review and Bayesian network meta-analysis","volume":"167","author":"Seeto","year":"2023","journal-title":"Bone"},{"key":"2025021815502595800_dgae173-B24","doi-asserted-by":"crossref","first-page":"e068033","DOI":"10.1136\/bmj-2021-068033","article-title":"Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials","volume":"381","author":"Handel","year":"2023","journal-title":"BMJ"},{"issue":"7","key":"2025021815502595800_dgae173-B25","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1111\/os.13136","article-title":"Romosozumab versus teriparatide for the treatment of postmenopausal osteoporosis: a systematic review and meta-analysis through a grade analysis of evidence","volume":"13","author":"Tian","year":"2021","journal-title":"Orthop Surg"},{"key":"2025021815502595800_dgae173-B26","doi-asserted-by":"crossref","first-page":"115121","DOI":"10.1016\/j.bone.2019.115121","article-title":"Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: systematic review and meta- analysis","volume":"130","author":"Lv","year":"2020","journal-title":"Bone"},{"issue":"11","key":"2025021815502595800_dgae173-B27","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1007\/s10067-020-04948-1","article-title":"Efficacy and safety of romosozumab in treatment for low bone mineral density: a systematic review and meta-analysis","volume":"39","author":"Kaveh","year":"2020","journal-title":"Clin Rheumatol"},{"issue":"6","key":"2025021815502595800_dgae173-B28","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/pds.5594","article-title":"Evaluation of the efficacy and safety of romosozumab (evenity) for the treatment of osteoporotic vertebral compression fracture in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials (CDM-J)","volume":"32","author":"Huang","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"2025021815502595800_dgae173-B29","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.3390\/jcm10081660","article-title":"Cardiovascular safety profile of romosozumab: a pharmacovigilance analysis of the US food and drug administration adverse event reporting system (FAERS)","volume":"10","author":"Vestergaard Kvist","year":"2021","journal-title":"J Clin Med"},{"issue":"4","key":"2025021815502595800_dgae173-B30","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/14740338.2023.2130891","article-title":"A pharmacovigilance analysis of FDA adverse event reporting system events for romosozumab","volume":"22","author":"Chen","year":"2023","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"2025021815502595800_dgae173-B31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/87551225221144960","article-title":"Evaluation of risk of cardiac or cerebrovascular events in romosozumab users focusing on comorbidities: analysis of the Japanese adverse drug event report database","volume":"39","author":"Kotake","year":"2023","journal-title":"J Pharm Technol"},{"issue":"5","key":"2025021815502595800_dgae173-B32","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/jbmr.4001","article-title":"Serious adverse events with romosozumab use in Japanese patients: need for clear formulation of contraindications worldwide","volume":"35","author":"Kawaguchi","year":"2020","journal-title":"J Bone Miner Res"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgae173\/61217100\/dgae173.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/3\/e861\/61217100\/dgae173.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/3\/e861\/61217100\/dgae173.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T11:10:42Z","timestamp":1739877042000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/110\/3\/e861\/7628384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,14]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3,14]]},"published-print":{"date-parts":[[2025,2,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgae173","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,3,14]]}}}